Date published: 2025-9-10

1-800-457-3801

SCBT Portrait Logo
Seach Input

GBP6 Inhibitors

Guanylate-binding protein 6 (GBP6) is a member of the guanylate-binding protein (GBP) family, which are large GTPases known primarily for their involvement in the host's innate immune defense mechanisms. These proteins are especially vital for the defense against various pathogens, such as bacteria and protozoa. Given the significant role of GBP6 in innate immunity, any compound that hinders its expression or function could have a profound impact on these natural defense mechanisms. Guanylate-binding protein 6 Inhibitors consists of chemicals that specifically target the expression, function, or activity of GBP6. Many of these inhibitors might operate by modulating pathways responsible for the induction or action of GBP6. For example, some compounds, like JAK inhibitors, affect interferon signaling, which is a primary inducer of GBP6. By hampering this signaling, they could potentially reduce the expression of GBP6. Similarly, other inhibitors that target cellular pathways like PI3K, JNK, p38 MAPK, and mTOR could indirectly affect GBP6 expression by influencing cellular responses and signaling cascades that culminate in GBP6 induction. Furthermore, broad-spectrum kinase inhibitors might have an overarching impact on various cellular signaling pathways, potentially suppressing multiple routes leading to GBP6 expression. The precise mechanisms of these inhibitors in relation to GBP6 would, of course, require rigorous biochemical and cellular research to elucidate. Regardless, understanding the nuanced interplay between these inhibitors and GBP6 could provide invaluable insights into the intricate web of cellular signaling and immune responses.

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

hydroxychloroquine

118-42-3sc-507426
5 g
$56.00
1
(0)

Hydroxychloroquine has been shown to inhibit certain cellular processes and immune responses. It might affect the pathways leading to the induction of GBP6 by interferons, potentially reducing its expression.

Ruxolitinib

941678-49-5sc-364729
sc-364729A
sc-364729A-CW
5 mg
25 mg
25 mg
$246.00
$490.00
$536.00
16
(1)

Ruxolitinib is a Janus kinase (JAK) inhibitor. Since JAKs are involved in interferon signaling, inhibiting them could reduce the expression of interferon-induced proteins, including GBP6.

BAY 11-7082

19542-67-7sc-200615B
sc-200615
sc-200615A
5 mg
10 mg
50 mg
$61.00
$83.00
$349.00
155
(1)

BAY 11-7082 is an inhibitor of NF-κB activation. Since NF-κB plays a role in immune responses and could be upstream of GBP6 expression, this compound might inhibit GBP6 expression.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$121.00
$392.00
148
(1)

LY294002 inhibits PI3K, which is involved in several cellular signaling pathways. This could potentially reduce the induction of GBP6 by interfering with signaling pathways responsible for its expression.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$65.00
$267.00
257
(3)

SP600125 is a JNK inhibitor. As JNK is involved in several cellular responses and immune signaling pathways, inhibiting it might impact the expression of GBP6.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$88.00
$342.00
284
(5)

SB203580 inhibits p38 MAPK, which plays roles in inflammation and immune responses. Inhibiting p38 MAPK may affect pathways leading to GBP6 expression.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$39.00
$90.00
212
(2)

PD98059 inhibits MEK, which is part of the ERK pathway. Since the ERK pathway has roles in various cellular functions, its inhibition might reduce GBP6 expression indirectly.

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$66.00
$219.00
$417.00
97
(3)

Wortmannin is a PI3K inhibitor. By inhibiting PI3K-mediated signaling pathways, it might reduce the expression of proteins induced by interferons, including GBP6.

Staurosporine

62996-74-1sc-3510
sc-3510A
sc-3510B
100 µg
1 mg
5 mg
$82.00
$150.00
$388.00
113
(4)

Staurosporine is a broad-spectrum kinase inhibitor. Its wide range of targets means it could potentially inhibit pathways leading to GBP6 expression.

U-0126

109511-58-2sc-222395
sc-222395A
1 mg
5 mg
$63.00
$241.00
136
(2)

U0126 inhibits MEK1 and MEK2. This could affect the ERK pathway and, in turn, potentially the expression of GBP6.